Divi's Laboratories Share Price
- Advice
- Hold
Start SIP in Divi's Laboratories
Start SIPDivi's Laboratories Performance
Day Range
- Low 5,436
- High 5,560
52 Week Range
- Low 3,295
- High 5,560
- Open Price5,479
- Previous Close5,479
- Volume529121
Divi's Laboratories F&O
Divi's Laboratories Investment Rating
-
Master Rating:
-
Divis Laboratories (Nse) has an operating revenue of Rs. 8,185.00 Cr. on a trailing 12-month basis. An annual revenue growth of 1% is not great, Pre-tax margin of 28% is great, ROE of 11% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 12% and 32% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 67 which is a FAIR score but needs to improve its earnings, a RS Rating of 66 which is FAIR indicating the recent price performance, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 59 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock definitely has some strength, you may want to examine it in more detail.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Indicator | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
---|---|---|---|---|---|---|
Oper Rev Qtr Cr | 2,063 | 2,259 | 1,808 | 1,868 | 1,730 | 1,908 |
Operating Expenses Qtr Cr | 1,442 | 1,542 | 1,317 | 1,394 | 1,239 | 1,419 |
Operating Profit Qtr Cr | 621 | 717 | 491 | 474 | 491 | 489 |
Depreciation Qtr Cr | 97 | 94 | 95 | 94 | 93 | 87 |
Interest Qtr Cr | 0 | 2 | 0 | 1 | 0 | 0 |
Tax Qtr Cr | 173 | 169 | 132 | 122 | 133 | 149 |
Net Profit Qtr Cr | 430 | 531 | 358 | 342 | 345 | 319 |
Divi's Laboratories Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 15
- Bearish Moving Average
- ___
- 1
- 20 Day
- ₹5,199.05
- 50 Day
- ₹4,934.24
- 100 Day
- ₹4,638.89
- 200 Day
- ₹4,298.16
- 20 Day
- ₹5,152.23
- 50 Day
- ₹4,887.94
- 100 Day
- ₹4,576.14
- 200 Day
- ₹4,132.89
Divi's Laboratories Resistance and Support
Resistance | |
---|---|
First Resistance | 5,529.47 |
Second Resistance | 5,606.73 |
Third Resistance | 5,653.47 |
RSI | 73.54 |
MFI | 84.59 |
MACD Single Line | 147.45 |
MACD | 178.66 |
Support | |
---|---|
First Support | 5,405.47 |
Second Support | 5,358.73 |
Third Supoort | 5,281.47 |
Divi's Laboratories Delivery and Volume
Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
---|---|---|---|
Day | 536,869 | 23,557,812 | 43.88 |
Week | 516,250 | 23,102,205 | 44.75 |
1 Month | 554,125 | 23,040,519 | 41.58 |
6 Month | 605,399 | 30,245,728 | 49.96 |
Divi's Laboratories Result Highlights
Divi's Laboratories Synopsis
NSE-Medical-Generic Drugs
Divi's Lab is involved in the business activities of Manufacture of other pharmaceutical and botanical products like hina powder etc.. Company’s Total Operating Revenue is Rs. 7665.00 Cr. and Equity Capital is Rs. 53.00 Cr. for the Year ended 31/03/2024. Divi's Laboratories Ltd. is a Public Limited Listed company incorporated on 12/10/1990 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24110TG1990PLC011854 and registration number is 011854.Market Cap | 145,460 |
Sales | 7,998 |
Shares in Float | 12.74 |
No of funds | 720 |
Yield | 0.55 |
Book Value | 10.77 |
U/D Vol ratio | 2 |
LTDebt / Equity | |
Alpha | 0.08 |
Beta | 0.63 |
Divi's Laboratories Shareholding Pattern
Owner Name | Jun-24 | Mar-24 | Dec-23 | Sep-23 |
---|---|---|---|---|
Promoters | 51.9% | 51.92% | 51.92% | 51.93% |
Mutual Funds | 13.1% | 14.28% | 13.72% | 13.62% |
Insurance Companies | 8.03% | 7.24% | 7.21% | 7.17% |
Foreign Portfolio Investors | 16.16% | 14.68% | 14.85% | 14.6% |
Financial Institutions/ Banks | 0.22% | 0.18% | ||
Individual Investors | 7.76% | 8.68% | 8.85% | 9.02% |
Others | 3.05% | 3.2% | 3.23% | 3.48% |
Divi's Laboratories Management
Name | Designation |
---|---|
Dr. Ramesh B V Nimmagadda | Non Exe.Chairman&Ind.Director |
Dr. Murali K Divi | Managing Director |
Dr. Kiran S Divi | WholeTime Director & CEO |
Ms. Nilima Prasad Divi | Whole Time Director |
Dr. S Devendra Rao | Whole Time Director |
Mr. N V Ramana | Executive Director |
Mr. K V Chowdary | Independent Director |
Dr. S Ganapaty | Independent Director |
Prof. Sunaina Singh | Independent Director |
Dr. Rajendra Kumar Premchand | Independent Director |
Mr. K V K Seshavataram | Independent Director |
Divi's Laboratories Forecast
Price Estimates
Divi's Laboratories Corporate Action
Date | Purpose | Remarks |
---|---|---|
2024-08-03 | Quarterly Results | |
2024-05-25 | Audited Results & Dividend | |
2024-02-10 | Quarterly Results | |
2023-11-06 | Quarterly Results | |
2023-08-14 | Quarterly Results |
Date | Purpose | Remarks |
---|---|---|
2024-08-02 | FINAL | Rs.30.00 per share(1500%)Final Dividend |
2023-08-11 | FINAL | Rs.30.00 per share(1500%)Final Dividend |
2022-08-12 | FINAL | Rs.30.00 per share(1500%)Dividend |
About Divi's Laboratories
Divi's Laboratories FAQs
What is Share Price of Divi's Laboratories ?
Divi's Laboratories share price is ₹5,452 As on 18 September, 2024 | 02:24
What is the Market Cap of Divi's Laboratories ?
The Market Cap of Divi's Laboratories is ₹144738.8 Cr As on 18 September, 2024 | 02:24
What is the P/E ratio of Divi's Laboratories ?
The P/E ratio of Divi's Laboratories is 86.5 As on 18 September, 2024 | 02:24
What is the PB ratio of Divi's Laboratories ?
The PB ratio of Divi's Laboratories is 10.6 As on 18 September, 2024 | 02:24
What does Divis Laboratories do?
Divis Laboratories Ltd is an active pharmaceutical ingredient (API) and intermediates company situated in India. Divis Laboratories specialises in the production of leading generic chemicals, nutraceutical components, and custom API and intermediate synthesis for worldwide innovators.
Is Divis Laboratories good for the long term?
Divis Laboratories has an operating revenue of INR 7,437.78 Cr. on a trailing 12-month basis. Annual revenue growth of 26% is outstanding, Pre-tax margin of 38% is great, ROE of 21% is exceptional. Institutional holding in Divis Laboratories has gone up in the last reported quarter is a positive sign. As per analysts rating in the last 6 months, the recommendation is to HOLD Divis Laboratories.
Is Divis Laboratories debt-free?
Divis Laboratories is debt-free and has a strong balance sheet enabling it to report stable earnings growth across business cycles.
Who is the owner of Divis Laboratories?
Murali Divi is the founder of Divis Laboratories, one of the top three manufacturers of active pharmaceutical ingredients (API).
How to buy Divis Laboratory?
You can easily buy Divis Laboratory shares by registering at 5Paisa and by setting up a Demat account in your name.